Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 52

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 52
---
, without realizing any of the benefits of having completed the Divestiture, will be subject to a number of risks, including the following:

| • |     | the trading price of our common stock could decline; |

| • |     | if the Divestiture Agreement is terminated and our board of directors seek another strategic transaction, our 
 stockholders cannot be certain that we will be able to find a party willing to enter into a transaction       |

- 35 -

| on terms equivalent to or more attractive than the terms that Kaken has agreed to in the Divestiture Agreement, if at all; |

| • |     | our ability to consummate any other strategic transaction separate from the Divestiture may be adversely affected 
 and our board of directors may decide to pursue a dissolution and liquidation;                                    |

| • |     | time and resources, financial and otherwise, committed by our management to matters relating to the Divestiture 
 could otherwise have been devoted to pursuing other beneficial opportunities;                                   |

| • |     | failure to receive the consideration from the Divestiture could materially and adversely impact our liquidity; |

| • |     | we may experience negative reactions from the financial markets or from our customers, suppliers, partners or 
 employees; and                                                                                                |

| • |     | we will generally be required to pay our expenses relating to the Divestiture, such as legal, accounting and 
 financial advisory fees, whether or not the Divestiture is completed.                                        |

In addition, if the Divestiture is not completed, we could be subject to litigation related to any failure to complete the Divestiture or related to any enforcement proceeding commenced against us to perform our obligations under the Divestiture Agreement. Any of these risks could materially and adversely impact our business, financial condition, results of operations and the trading price of shares of our common stock. Similarly, delays in the completion of the Divestiture could, among other things, result in additional transaction costs or other negative effects associated with the delays and uncertainty about the completion of the Divestiture and could materially and adversely impact our business, financial condition, results of operations and the trading price of shares of our common stock. While the Divestiture is pending, we are subject to business uncertainties and contractual restrictions that could harm our business relationships, financial condition, results of operations, and business. During the period prior to the completion of the Divestiture and pursuant to the terms of the Divestiture Agreement, our business is exposed to certain inherent risks and